Skip to main content
. 2011 Nov 9;2(11):850–861. doi: 10.18632/oncotarget.347

Figure 2. Prognostic impact of DNMT3A exon 23 mutations in 194 AML patients with intermediate-cytogenetic risk.

Figure 2

(A) Disease-free (DFS) and (B) overall survival (OS) in patients with or without DNMT3A exon 23 mutations. DFS and OS were not different between DNMT3A exon 23+ and DNMT3A exon 23- patients (p=0.16 and p=0.17, respectively).